BiotechTube

Ad26.ZEBOV + MVA-BN-Filo

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemorrhagic Fever, Ebola

Conditions

Hemorrhagic Fever, Ebola

Trial Timeline

May 31, 2016 → Dec 13, 2021

NCT ID
NCT02661464

About Ad26.ZEBOV + MVA-BN-Filo

Ad26.ZEBOV + MVA-BN-Filo is a phase 3 stage product being developed by Bavarian Nordic for Hemorrhagic Fever, Ebola. The current trial status is terminated. This product is registered under clinical trial identifier NCT02661464. Target conditions include Hemorrhagic Fever, Ebola.

What happened to similar drugs?

0 of 1 similar drugs in Hemorrhagic Fever, Ebola were approved

Approved (0) Terminated (0) Active (1)
🔄Tranexamic acid first, than placebo + First placebo, than Tranexamic acid.BaxterPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02661464Phase 3Terminated

Competing Products

10 competing products in Hemorrhagic Fever, Ebola

See all competitors
ProductCompanyStageHype Score
LP-10Lipella PharmaceuticalsPhase 2
25
BAF312 solution + Matching Placebo for BAF312 solution + BAF312 tablet + Matching Placebo for BAF312 tabletNovartisPhase 2
35
ALN-6400 + PlaceboAlnylam PharmaceuticalsPhase 1/2
36
AVI-7537United TherapeuticsPhase 1
18
AVI-7288United TherapeuticsPhase 1
26
Placebo + AVI-6002United TherapeuticsPhase 1
26
AVI-6003 + PlaceboUnited TherapeuticsPhase 1
26
Tranexamic acid first, than placebo + First placebo, than Tranexamic acid.BaxterPhase 3
37
Ribavirin (Virazole) InjectionBausch HealthPhase 2
21
BGE-117, 4mg + BGE-117, 12mgBioAge LabsPhase 2
21